1. Home
  2. ICCC vs RAND Comparison

ICCC vs RAND Comparison

Compare ICCC & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICCC
  • RAND
  • Stock Information
  • Founded
  • ICCC 1982
  • RAND 1969
  • Country
  • ICCC United States
  • RAND United States
  • Employees
  • ICCC N/A
  • RAND N/A
  • Industry
  • ICCC Biotechnology: Pharmaceutical Preparations
  • RAND Finance: Consumer Services
  • Sector
  • ICCC Health Care
  • RAND Finance
  • Exchange
  • ICCC Nasdaq
  • RAND Nasdaq
  • Market Cap
  • ICCC 35.4M
  • RAND 38.1M
  • IPO Year
  • ICCC 1987
  • RAND N/A
  • Fundamental
  • Price
  • ICCC $4.29
  • RAND $17.08
  • Analyst Decision
  • ICCC
  • RAND
  • Analyst Count
  • ICCC 0
  • RAND 0
  • Target Price
  • ICCC N/A
  • RAND N/A
  • AVG Volume (30 Days)
  • ICCC 6.8K
  • RAND 2.4K
  • Earning Date
  • ICCC 08-08-2024
  • RAND 08-02-2024
  • Dividend Yield
  • ICCC N/A
  • RAND 6.52%
  • EPS Growth
  • ICCC N/A
  • RAND 232.84
  • EPS
  • ICCC N/A
  • RAND 2.23
  • Revenue
  • ICCC $21,282,719.00
  • RAND $7,553,884.00
  • Revenue This Year
  • ICCC N/A
  • RAND N/A
  • Revenue Next Year
  • ICCC N/A
  • RAND N/A
  • P/E Ratio
  • ICCC N/A
  • RAND $7.98
  • Revenue Growth
  • ICCC 32.89
  • RAND 16.36
  • 52 Week Low
  • ICCC $4.05
  • RAND $12.50
  • 52 Week High
  • ICCC $5.87
  • RAND $19.60
  • Technical
  • Relative Strength Index (RSI)
  • ICCC 46.74
  • RAND 59.86
  • Support Level
  • ICCC $4.10
  • RAND $16.88
  • Resistance Level
  • ICCC $4.56
  • RAND $17.79
  • Average True Range (ATR)
  • ICCC 0.14
  • RAND 0.58
  • MACD
  • ICCC 0.01
  • RAND 0.27
  • Stochastic Oscillator
  • ICCC 25.33
  • RAND 81.08

About ICCC ImmuCell Corporation

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

About RAND Rand Capital Corporation

Rand Capital Corp is a closed-end, diversified management company. The firm's investment objectives is to maximize the total return to the shareholders with current income combined with capital appreciation. Some of its portfolios include lumious, and GiveGab among others.

Share on Social Networks: